Table 1.
Baseline characteristics of patients in the TACE group and the TACE-RFA group
| Characteristic | TACE group (n = 271) | TACE-RFA group (n = 128) |
P value |
|---|---|---|---|
| Sex | 0.242 | ||
| Male | 216 (79.7%) | 109 (85.2%) | |
| Female | 55 (20.3%) | 19 (14.8%) | |
| Age (years) | 0.476 | ||
| Mean value | 56.1 ± 10.8 | 55.3 ± 10.4 | |
| Range | 28–79 | 16–83 | |
| Albumin g/dL | 37.8 ± 4.9 | 38.0 ± 5.9 | 0.692 |
| Total bilirubin u mol/L | 20.1 ± 17.5 | 24.0 ± 54.4 0 | 0.435 |
| Alpha-fetoprotein level | 0.443 | ||
| < =400 ng/mL | 180 (66.4%) | 80 (62.5%) | |
| > 400 ng/mL | 91 (33.6%) | 48 (37.5%) | |
| Child-Pugh score | 0.676 | ||
| A | 239 (88.2%) | 111 (86.7%) | |
| B | 32 (11.8%) | 17 (13.3%) | |
| BCLC stage | 0.000 | ||
| A | 110 (40.6%) | 88 (68.8%) | |
| B | 161 (59.4%) | 40 (31.2%) | |
| Liver disease type | 0.504 | ||
| Hepatitis B | 242 (89.3%) | 109 (85.2%) | |
| Hepatitis C | 9 (3.3%) | 6 (4.7%) | |
| Other | 20 (7.4%) | 13 (10.2%) | |
| Mean tumor diameter (cm) | 6.8 ± 4.3 | 4.5 ± 3.1 | 0.000 |
| Tumor diameter range (cm) | 0.000 | ||
| < =3.0 | 70 (25.8%) | 50 (39.1%) | |
| 3.1–5.0 | 50 (18.5%) | 40 (31.2%) | |
| 5.1–10.0 | 89 (32.8%) | 27 (21.1%) | |
| > 10 | 62 (22.9%) | 11 (8.6%) | |
| Number of tumors | 0.102 | ||
| 1 | 201 (74.2%) | 102 (79.7%) | |
| 2 | 49 (18.1%) | 23 (18.0%) | |
| 3 | 21 (7.7%) | 3 (2.3%) |
BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization